Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.19 USD | -1.40% | +16.39% | -5.21% |
May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 204.96 and 25.02 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.21% | 2.38B | C- | ||
+25.69% | 48.09B | B- | ||
+46.90% | 40.62B | A | ||
-3.46% | 40.43B | B | ||
-6.20% | 28.36B | C | ||
+9.17% | 24.89B | B- | ||
-20.42% | 19.01B | B | ||
+28.07% | 12.09B | C+ | ||
+0.17% | 11.88B | B+ | ||
-1.24% | 11.8B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TGTX Stock
- Ratings TG Therapeutics, Inc.